Abstract
The present investigations demonstrate that development of new novel HDAC inhibitor to specific HDAC 8 disruption. The novel compound having similar structure of protein – protein interfaces of NCoR-SIN 3 – HDAC complexes. Hydroxamic acid is a new effective drug targets for acute promyelocytic leukemia (APL) and T-cell lymphoma. The hydroxamic acid based newly designed certain indole and Biphenyl derivatives was screened against HDAC8 inhibition assay, in this result the compound number 10 and 11 was showing most active compound as a comparison of trichostatin-A.
